- Home
- Publications
- Publication Search
- Publication Details
Title
Antiobesity Pharmacotherapy in Adults with Chronic Kidney Disease
Authors
Keywords
-
Journal
KIDNEY INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-11-04
DOI
10.1016/j.kint.2023.10.014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo
- (2023) Katherine R. Tuttle et al. KIDNEY INTERNATIONAL
- The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
- (2023) Peter Rossing et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
- (2023) Hiddo J.L. Heerspink et al. DIABETES CARE
- Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
- (2023) Hiddo J.L. Heerspink et al. DIABETES CARE
- Medicare Part D Coverage of Antiobesity Medications — Challenges and Uncertainty Ahead
- (2023) Khrysta Baig et al. NEW ENGLAND JOURNAL OF MEDICINE
- Benefits of bariatric surgery on microvascular outcomes in adult patients with type 2 diabetes: a systematic review and meta-analysis
- (2023) Javier Obeso-Fernández et al. Surgery for Obesity and Related Diseases
- Prevalence of Chronic Kidney Disease in China
- (2023) Limin Wang et al. JAMA Internal Medicine
- Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
- (2023) Vanita R Aroda et al. LANCET
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
- (2023) Julio Rosenstock et al. LANCET
- Unanswered questions about the causes of obesity
- (2023) John R. Speakman et al. SCIENCE
- Sleeve gastrectomy in subjects with severe obesity and baseline chronic kidney disease improves kidney function independently of weight loss. A propensity score matched analysis
- (2022) David Romero Funes et al. Surgery for Obesity and Related Diseases
- Incidence and Characteristics of Remission of Type 2 Diabetes in England: A Cohort Study Using the National Diabetes Audit
- (2022) Naomi Holman et al. DIABETES CARE
- Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study
- (2022) Violeta Raverdy et al. Lancet Diabetes & Endocrinology
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obesity-Related Chronic Kidney Disease: Principal Mechanisms and New Approaches in Nutritional Management
- (2022) Alessandra Stasi et al. Frontiers in Nutrition
- Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society
- (2022) Allon N. Friedman et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
- (2022) Tamer Coskun et al. Cell Metabolism
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
- (2022) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Prevalence of Obesity and CKD Among Adults in the United States, 2017-2020
- (2022) Allon N. Friedman et al. Kidney Medicine
- Management of Obesity in Adults with CKD
- (2021) Allon N. Friedman et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential kidney protection with liraglutide and semaglutide – exploratory mediation analysis
- (2021) Johannes F. E. Mann et al. DIABETES OBESITY & METABOLISM
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- Phentermine-Induced Acute Kidney Injury Secondary to Uncontrolled Hypertension in a Patient with Weight Regain Post-bariatric Surgery
- (2021) Marvin Wei Jie Chua et al. OBESITY SURGERY
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural Brain Changes Associated with Overweight and Obesity
- (2021) Erick Gómez-Apo et al. Journal of Obesity
- Rare genetic causes of obesity: Diagnosis and management in clinical care
- (2021) Béatrice Dubern et al. ANNALES D ENDOCRINOLOGIE
- Anti-obesity drug discovery: advances and challenges
- (2021) Timo D. Müller et al. NATURE REVIEWS DRUG DISCOVERY
- SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials
- (2021) Alex Jia Yang Cheong et al. Obesity
- Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020
- (2021) Abdulrahman Alsuhibani et al. International Journal of Clinical Pharmacy
- Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
- (2021) Soraya Puglisi et al. Frontiers in Endocrinology
- Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease
- (2020) Johannes F.E. Mann et al. Clinical Journal of the American Society of Nephrology
- Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
- (2020) Rory J. McCrimmon et al. DIABETOLOGIA
- GLP-1 Alleviates Diabetic Kidney Disease Through Activation of Autophagy by Regulating AMPK/mTOR Pathway
- (2020) Shuangli Yang et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control
- (2020) Flavia L. Martins et al. HYPERTENSION
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
- (2020) Karine Clément et al. Lancet Diabetes & Endocrinology
- The relationship between kidney function and body mass index before and after bariatric surgery in patients with chronic kidney disease
- (2020) Heidi Fischer et al. Surgery for Obesity and Related Diseases
- Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium
- (2019) Alex R Chang et al. BMJ-British Medical Journal
- Metabolic surgery improves renal injury independent of weight loss: a meta-analysis
- (2019) Katharina M. Scheurlen et al. Surgery for Obesity and Related Diseases
- A comprehensive diagnostic approach to detect underlying causes of obesity in adults
- (2019) Eline S. van der Valk et al. Obesity Reviews
- Higher body mass index is associated with incident diabetes and chronic kidney disease independent of genetic confounding
- (2019) Hong Xu et al. KIDNEY INTERNATIONAL
- Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-α-mediated NF-κB and MAPK pathway
- (2019) Yongjian Ye et al. Obesity Research & Clinical Practice
- The Association Between Kidney Disease and Diabetes Remission in Bariatric Surgery Patients With Type 2 Diabetes
- (2019) Allon N. Friedman et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study
- (2019) Richard E. Pratley et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor pathway inhibits extracellular matrix production by mesangial cells through store-operated Ca2+ channel
- (2019) Linjing Huang et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007–2015: A registry-based cohort study
- (2019) Anders Jans et al. PLOS MEDICINE
- Podocyte hypertrophic stress and detachment precedes hyperglycemia or albuminuria in a rat model of obesity and type2 diabetes-associated nephropathy
- (2019) Akihiro Minakawa et al. Scientific Reports
- Impact of Obesity on Modality Longevity, Residual Kidney Function, Peritonitis, and Survival Among Incident Peritoneal Dialysis Patients
- (2018) Yoshitsugu Obi et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
- (2018) Charlotte Granhall et al. CLINICAL PHARMACOKINETICS
- Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
- (2018) Michael EJ Lean et al. LANCET
- Maintenance of Lost Weight and Long-Term Management of Obesity
- (2018) Kevin D. Hall et al. MEDICAL CLINICS OF NORTH AMERICA
- Obesity and chronic kidney disease: A population-based study among South Koreans
- (2018) Lorraine S. Evangelista et al. PLoS One
- GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis
- (2018) Chengshi Wang et al. PLoS One
- Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2018) Johannes F. E. Mann et al. CIRCULATION
- FSGS as an Adaptive Response to Growth-Induced Podocyte Stress
- (2017) Ryuzoh Nishizono et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health Effects of Overweight and Obesity in 195 Countries over 25 Years
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Complementary Hypotheses on Contributors to the Obesity Epidemic
- (2017) Rachel A.H. Davis et al. Obesity
- Effect of Roux-en-Y gastric bypass and diet-induced weight loss on diabetic kidney disease in the Zucker diabetic fatty rat
- (2017) Karl J. Neff et al. Surgery for Obesity and Related Diseases
- Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
- (2016) Karly C. Sourris et al. CURRENT DRUG TARGETS
- Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease
- (2016) B. Buysschaert et al. DIABETES & METABOLISM
- The effect of liraglutide on renal function: A randomized clinical trial
- (2016) Bernt J. von Scholten et al. DIABETES OBESITY & METABOLISM
- Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
- (2016) Amalia Gastaldelli et al. HEPATOLOGY
- Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis
- (2016) Vivette D. D'Agati et al. Nature Reviews Nephrology
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Impact of Obesity on Allograft Failure After Kidney Transplantation
- (2016) Abhijit S. Naik et al. TRANSPLANTATION
- Position of the Academy of Nutrition and Dietetics: Obesity, Reproduction, and Pregnancy Outcomes
- (2016) Jamie Stang et al. Journal of the Academy of Nutrition and Dietetics
- Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis
- (2015) Jeffrey A Lafranca et al. BMC Medicine
- Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial
- (2015) Melanie J. Davies et al. DIABETES CARE
- Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blinded, Parallel Group, Randomized Trial
- (2015) Thomas Idorn et al. DIABETES CARE
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- When Arteriovenous Fistulas Are Too Deep: Options in Obese Individuals
- (2015) C. Miles Maliska et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Leptin Mediates the Increase in Blood Pressure Associated with Obesity
- (2014) Stephanie E. Simonds et al. CELL
- Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008–12 National Health Examination Survey
- (2014) Luca De Nicola et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of Hemodialysis on Plasma Glucose Profile and Plasma Level of Liraglutide in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease: A Pilot Study
- (2014) Takeshi Osonoi et al. PLoS One
- Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease
- (2014) Aiko P J de Vries et al. Lancet Diabetes & Endocrinology
- Role of advanced glycation end products in cellular signaling
- (2014) Christiane Ott et al. Redox Biology
- Predicting the Glomerular Filtration Rate in Bariatric Surgery Patients
- (2013) Allon N. Friedman et al. AMERICAN JOURNAL OF NEPHROLOGY
- Short-Term Changes after a Weight Reduction Intervention in Advanced Diabetic Nephropathy
- (2013) A. N. Friedman et al. Clinical Journal of the American Society of Nephrology
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- The Glucagon-Like Peptide-1 Receptor Agonist, Liraglutide, Attenuates the Progression of Overt Diabetic Nephropathy in Type 2 Diabetic Patients
- (2013) Shigeki Imamura et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Mechanisms underlying current and future anti-obesity drugs
- (2013) Roger A.H. Adan TRENDS IN NEUROSCIENCES
- Body Mass Index in 1.2 Million Adolescents and Risk for End-Stage Renal Disease
- (2012) Asaf Vivante et al. ARCHIVES OF INTERNAL MEDICINE
- Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes
- (2012) Edward W. Gregg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Causes of obesity
- (2012) Suzanne M. Wright et al. Abdominal Radiology
- Orlistat and Acute Kidney Injury: An Analysis of 953 Patients
- (2011) Matthew A. Weir ARCHIVES OF INTERNAL MEDICINE
- Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
- (2011) J. Dushay et al. DIABETES CARE
- Fatty Kidney, Hypertension, and Chronic Kidney Disease
- (2011) Meredith C. Foster et al. HYPERTENSION
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Rhabdomyolysis associated with phentermine
- (2010) K. E. Steidl et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- Nonrandomized Trial of Weight Loss With Orlistat, Nutrition Education, Diet, and Exercise in Obese Patients With CKD: 2-Year Follow-up
- (2009) Helen L. MacLaughlin et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
- (2009) Lisbeth V. Jacobsen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Challenges of Treating a 466-Kilogram Man With Acute Kidney Injury
- (2008) Allon N. Friedman et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started